Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer

Antonino Musolino, Nadia Naldi, Maria Vittoria Dieci, Daniele Zanoni, Anita Rimanti, D. Boggiani, P. Sgargi, Daniele Generali, Federico Piacentini, M. Ambroggi, Katia Cagossi, Luca Gianni, Samanta Sarti, Giancarlo Bisagni, A. Ardizzoni, Pierfranco Conte, Valentina Guarneri

Research output: Contribution to journalArticle

Abstract

Lapatinib enhances antibody-dependent cell-mediated cytotoxicity (ADCC) activity of trastuzumab. FcγR polymorphisms have been associated with both ADCC and clinical activity of trastuzumab in HER2+ breast cancer (BC) patients (pts). We analyzed FcγRIIa-H131R and FcγRIIIa-V158F polymorphisms in the CHER-LOB trial population of HER2+ BCs treated with preoperative chemotherapy plus trastuzumab (arm A), lapatinib (arm B) or both (arm C). Genotyping was successfully performed in 73/121 (60%) pts. A significant improvement in pathological complete response (pCR) rate was observed for the combination arm C, but only in FcγRIIIa V allele carriers (C vs A, 67 vs 27%, P=0.043; C vs B, 67 vs 22%, P=0.012). An independent interaction between arm C and FcγRIIIa V allele was found for pCR (odds ratio=9.4; 95% confidence interval, 2.3–39.6; P=0.003). No significant associations were observed between pCR and FcγRIIa polymorphism, and between pre-treatment tumor-infiltrating lymphocytes and FcγR polymorphisms. Our study provides evidence for a FcγRIIIa V allele-restricted pCR benefit from neoadjuvant trastuzumab plus lapatinib in HER2+ BC.The Pharmacogenomics Journal advance online publication, 5 July 2016; doi:10.1038/tpj.2016.51.

Original languageEnglish
JournalPharmacogenomics Journal
DOIs
Publication statusAccepted/In press - Jul 5 2016

Fingerprint

Immunoglobulin Fragments
Immunoglobulin G
Breast Neoplasms
Antibody-Dependent Cell Cytotoxicity
Drug Therapy
Alleles
Tumor-Infiltrating Lymphocytes
Pharmacogenetics
Publications
Odds Ratio
Confidence Intervals
lapatinib
Trastuzumab
Population
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Genetics

Cite this

Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer. / Musolino, Antonino; Naldi, Nadia; Dieci, Maria Vittoria; Zanoni, Daniele; Rimanti, Anita; Boggiani, D.; Sgargi, P.; Generali, Daniele; Piacentini, Federico; Ambroggi, M.; Cagossi, Katia; Gianni, Luca; Sarti, Samanta; Bisagni, Giancarlo; Ardizzoni, A.; Conte, Pierfranco; Guarneri, Valentina.

In: Pharmacogenomics Journal, 05.07.2016.

Research output: Contribution to journalArticle

Musolino, Antonino ; Naldi, Nadia ; Dieci, Maria Vittoria ; Zanoni, Daniele ; Rimanti, Anita ; Boggiani, D. ; Sgargi, P. ; Generali, Daniele ; Piacentini, Federico ; Ambroggi, M. ; Cagossi, Katia ; Gianni, Luca ; Sarti, Samanta ; Bisagni, Giancarlo ; Ardizzoni, A. ; Conte, Pierfranco ; Guarneri, Valentina. / Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer. In: Pharmacogenomics Journal. 2016.
@article{067ff90789d3461c98a8bb9237c536d7,
title = "Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer",
abstract = "Lapatinib enhances antibody-dependent cell-mediated cytotoxicity (ADCC) activity of trastuzumab. FcγR polymorphisms have been associated with both ADCC and clinical activity of trastuzumab in HER2+ breast cancer (BC) patients (pts). We analyzed FcγRIIa-H131R and FcγRIIIa-V158F polymorphisms in the CHER-LOB trial population of HER2+ BCs treated with preoperative chemotherapy plus trastuzumab (arm A), lapatinib (arm B) or both (arm C). Genotyping was successfully performed in 73/121 (60{\%}) pts. A significant improvement in pathological complete response (pCR) rate was observed for the combination arm C, but only in FcγRIIIa V allele carriers (C vs A, 67 vs 27{\%}, P=0.043; C vs B, 67 vs 22{\%}, P=0.012). An independent interaction between arm C and FcγRIIIa V allele was found for pCR (odds ratio=9.4; 95{\%} confidence interval, 2.3–39.6; P=0.003). No significant associations were observed between pCR and FcγRIIa polymorphism, and between pre-treatment tumor-infiltrating lymphocytes and FcγR polymorphisms. Our study provides evidence for a FcγRIIIa V allele-restricted pCR benefit from neoadjuvant trastuzumab plus lapatinib in HER2+ BC.The Pharmacogenomics Journal advance online publication, 5 July 2016; doi:10.1038/tpj.2016.51.",
author = "Antonino Musolino and Nadia Naldi and Dieci, {Maria Vittoria} and Daniele Zanoni and Anita Rimanti and D. Boggiani and P. Sgargi and Daniele Generali and Federico Piacentini and M. Ambroggi and Katia Cagossi and Luca Gianni and Samanta Sarti and Giancarlo Bisagni and A. Ardizzoni and Pierfranco Conte and Valentina Guarneri",
year = "2016",
month = "7",
day = "5",
doi = "10.1038/tpj.2016.51",
language = "English",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer

AU - Musolino, Antonino

AU - Naldi, Nadia

AU - Dieci, Maria Vittoria

AU - Zanoni, Daniele

AU - Rimanti, Anita

AU - Boggiani, D.

AU - Sgargi, P.

AU - Generali, Daniele

AU - Piacentini, Federico

AU - Ambroggi, M.

AU - Cagossi, Katia

AU - Gianni, Luca

AU - Sarti, Samanta

AU - Bisagni, Giancarlo

AU - Ardizzoni, A.

AU - Conte, Pierfranco

AU - Guarneri, Valentina

PY - 2016/7/5

Y1 - 2016/7/5

N2 - Lapatinib enhances antibody-dependent cell-mediated cytotoxicity (ADCC) activity of trastuzumab. FcγR polymorphisms have been associated with both ADCC and clinical activity of trastuzumab in HER2+ breast cancer (BC) patients (pts). We analyzed FcγRIIa-H131R and FcγRIIIa-V158F polymorphisms in the CHER-LOB trial population of HER2+ BCs treated with preoperative chemotherapy plus trastuzumab (arm A), lapatinib (arm B) or both (arm C). Genotyping was successfully performed in 73/121 (60%) pts. A significant improvement in pathological complete response (pCR) rate was observed for the combination arm C, but only in FcγRIIIa V allele carriers (C vs A, 67 vs 27%, P=0.043; C vs B, 67 vs 22%, P=0.012). An independent interaction between arm C and FcγRIIIa V allele was found for pCR (odds ratio=9.4; 95% confidence interval, 2.3–39.6; P=0.003). No significant associations were observed between pCR and FcγRIIa polymorphism, and between pre-treatment tumor-infiltrating lymphocytes and FcγR polymorphisms. Our study provides evidence for a FcγRIIIa V allele-restricted pCR benefit from neoadjuvant trastuzumab plus lapatinib in HER2+ BC.The Pharmacogenomics Journal advance online publication, 5 July 2016; doi:10.1038/tpj.2016.51.

AB - Lapatinib enhances antibody-dependent cell-mediated cytotoxicity (ADCC) activity of trastuzumab. FcγR polymorphisms have been associated with both ADCC and clinical activity of trastuzumab in HER2+ breast cancer (BC) patients (pts). We analyzed FcγRIIa-H131R and FcγRIIIa-V158F polymorphisms in the CHER-LOB trial population of HER2+ BCs treated with preoperative chemotherapy plus trastuzumab (arm A), lapatinib (arm B) or both (arm C). Genotyping was successfully performed in 73/121 (60%) pts. A significant improvement in pathological complete response (pCR) rate was observed for the combination arm C, but only in FcγRIIIa V allele carriers (C vs A, 67 vs 27%, P=0.043; C vs B, 67 vs 22%, P=0.012). An independent interaction between arm C and FcγRIIIa V allele was found for pCR (odds ratio=9.4; 95% confidence interval, 2.3–39.6; P=0.003). No significant associations were observed between pCR and FcγRIIa polymorphism, and between pre-treatment tumor-infiltrating lymphocytes and FcγR polymorphisms. Our study provides evidence for a FcγRIIIa V allele-restricted pCR benefit from neoadjuvant trastuzumab plus lapatinib in HER2+ BC.The Pharmacogenomics Journal advance online publication, 5 July 2016; doi:10.1038/tpj.2016.51.

UR - http://www.scopus.com/inward/record.url?scp=84977125803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977125803&partnerID=8YFLogxK

U2 - 10.1038/tpj.2016.51

DO - 10.1038/tpj.2016.51

M3 - Article

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

ER -